Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung.

McCullar B, Pandey M, Yaghmour G, Hare F, Patel K, Stein K, Feldman R, Chandler JC, Martin MG.

Breast Cancer Res Treat. 2016 Jul;158(1):195-202. doi: 10.1007/s10549-016-3867-z. Epub 2016 Jun 21. Erratum in: Breast Cancer Res Treat. 2019 Jan;173(1):243.

PMID:
27329168
2.

Genomic alterations in neuroendocrine cancers of the ovary.

Yaghmour G, Prouet P, Wiedower E, Jamy OH, Feldman R, Chandler JC, Pandey M, Martin MG.

J Ovarian Res. 2016 Aug 26;9(1):52. doi: 10.1186/s13048-016-0259-2.

3.

Identification of molecular targets in vulvar cancers.

Palisoul ML, Mullen MM, Feldman R, Thaker PH.

Gynecol Oncol. 2017 Aug;146(2):305-313. doi: 10.1016/j.ygyno.2017.05.011. Epub 2017 May 20.

PMID:
28536037
4.

Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.

Meagher NS, Schuster K, Voss A, Budden T, Pang CNI, deFazio A, Ramus SJ, Friedlander ML.

Gynecol Oncol. 2018 Sep;150(3):527-533. doi: 10.1016/j.ygyno.2018.07.013. Epub 2018 Jul 25.

5.

Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.

Muller KE, Marotti JD, de Abreu FB, Peterson JD, Miller TW, Chamberlin MD, Tsongalis GJ, Tafe LJ.

Exp Mol Pathol. 2016 Jun;100(3):421-5. doi: 10.1016/j.yexmp.2016.04.002. Epub 2016 Apr 16.

PMID:
27095739
6.

Assessment of topoisomerase II-alpha gene status by dual color chromogenic in situ hybridization in a set of Iraqi patients with invasive breast carcinoma.

Neama RAA, Habib MA, Ali SA, Al-Khafaji AH, Alqanbar MF.

Indian J Pathol Microbiol. 2017 Oct-Dec;60(4):475-480. doi: 10.4103/IJPM.IJPM_62_16.

7.

Correlation between ER, PR, HER-2, Bcl-2, p53, proliferative and apoptotic indexes with HER-2 gene amplification and TOP2A gene amplification and deletion in four molecular subtypes of breast cancer.

Mitrović O, Čokić V, Đikić D, Budeč M, Vignjević S, Subotički T, Gulan M, Radović S, Furtula S.

Target Oncol. 2014 Dec;9(4):367-79. doi: 10.1007/s11523-013-0297-2. Epub 2013 Nov 24.

PMID:
24272208
8.

Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.

Jing C, Mao X, Wang Z, Sun K, Ma R, Wu J, Cao H.

Mol Med Rep. 2018 Aug;18(2):2191-2197. doi: 10.3892/mmr.2018.9210. Epub 2018 Jun 22.

9.

HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas.

Aumayr K, Klatte T, Neudert B, Birner P, Shariat S, Schmidinger M, Susani M, Haitel A.

Pathol Oncol Res. 2018 Jul;24(3):575-581. doi: 10.1007/s12253-017-0260-0. Epub 2017 Jul 28.

PMID:
28755093
10.

Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.

Yang L, Ye F, Bao L, Zhou X, Wang Z, Hu P, Ouyang N, Li X, Shi Y, Chen G, Xia P, Chui M, Li W, Jia Y, Liu Y, Liu J, Ye J, Zhang Z, Bu H.

Cancer Sci. 2019 Apr;110(4):1389-1400. doi: 10.1111/cas.13976. Epub 2019 Mar 19.

11.

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.

Ross JS, Gay LM, Wang K, Ali SM, Chumsri S, Elvin JA, Bose R, Vergilio JA, Suh J, Yelensky R, Lipson D, Chmielecki J, Waintraub S, Leyland-Jones B, Miller VA, Stephens PJ.

Cancer. 2016 Sep 1;122(17):2654-62. doi: 10.1002/cncr.30102. Epub 2016 Jun 10.

12.

Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.

Kim JY, Lee E, Park K, Park WY, Jung HH, Ahn JS, Im YH, Park YH.

Oncotarget. 2017 Apr 25;8(17):27997-28007. doi: 10.18632/oncotarget.15881.

13.

Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.

Li G, Guo X, Chen M, Tang L, Jiang H, Day JX, Xie Y, Peng L, Xu X, Li J, Wang S, Xiao Z, Dai L, Wang J.

PLoS One. 2018 Sep 13;13(9):e0203495. doi: 10.1371/journal.pone.0203495. eCollection 2018.

14.

Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.

VanderLaan PA, Rangachari D, Mockus SM, Spotlow V, Reddi HV, Malcolm J, Huberman MS, Joseph LJ, Kobayashi SS, Costa DB.

Lung Cancer. 2017 Apr;106:17-21. doi: 10.1016/j.lungcan.2017.01.011. Epub 2017 Jan 25.

15.

Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.

Rekhtman N, Pietanza MC, Hellmann MD, Naidoo J, Arora A, Won H, Halpenny DF, Wang H, Tian SK, Litvak AM, Paik PK, Drilon AE, Socci N, Poirier JT, Shen R, Berger MF, Moreira AL, Travis WD, Rudin CM, Ladanyi M.

Clin Cancer Res. 2016 Jul 15;22(14):3618-29. doi: 10.1158/1078-0432.CCR-15-2946. Epub 2016 Mar 9.

16.

Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.

Chau NG, Li YY, Jo VY, Rabinowits G, Lorch JH, Tishler RB, Margalit DN, Schoenfeld JD, Annino DJ, Goguen LA, Thomas T, Becker H, Haddad T, Krane JF, Lindeman NI, Shapiro GI, Haddad RI, Hammerman PS.

Clin Cancer Res. 2016 Jun 15;22(12):2939-49. doi: 10.1158/1078-0432.CCR-15-2314. Epub 2016 Jan 13.

17.

Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.

Pang JB, Savas P, Fellowes AP, Mir Arnau G, Kader T, Vedururu R, Hewitt C, Takano EA, Byrne DJ, Choong DY, Millar EK, Lee CS, O'Toole SA, Lakhani SR, Cummings MC, Mann GB, Campbell IG, Dobrovic A, Loi S, Gorringe KL, Fox SB.

Mod Pathol. 2017 Jul;30(7):952-963. doi: 10.1038/modpathol.2017.21. Epub 2017 Mar 24.

18.

Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.

Ross JS, Badve S, Wang K, Sheehan CE, Boguniewicz AB, Otto GA, Yelensky R, Lipson D, Ali S, Morosini D, Chliemlecki J, Elvin JA, Miller VA, Stephens PJ.

Arch Pathol Lab Med. 2015 May;139(5):642-9. doi: 10.5858/arpa.2014-0200-OA.

19.

Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.

Nakauchi C, Kagara N, Shimazu K, Shimomura A, Naoi Y, Shimoda M, Kim SJ, Noguchi S.

Clin Breast Cancer. 2016 Oct;16(5):418-423. doi: 10.1016/j.clbc.2016.05.004. Epub 2016 May 14.

PMID:
27265061
20.

Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing.

Roy-Chowdhuri S, de Melo Gagliato D, Routbort MJ, Patel KP, Singh RR, Broaddus R, Lazar AJ, Sahin A, Alvarez RH, Moulder S, Wheler JJ, Janku F, Gonzalez-Angulo AM, Chavez-MacGregor M, Valero V, Ueno NT, Mills G, Mendelsohn J, Yao H, Aldape K, Luthra R, Meric-Bernstam F.

Am J Clin Pathol. 2015 Nov;144(5):713-21. doi: 10.1309/AJCPWDEQYCYC92JQ.

PMID:
26486734

Supplemental Content

Support Center